Similarly, a recent study from Hagiwara demonstrated that PARP1 has a good prediction effect as a biomarker to predict PD-L1 blockade response in PBRM1-mutated ccRCC patients, showing good prediction effect [196]. Here, PBRM1 is linked to nonpapillary renal cell carcinoma.